Advertisement

Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study

  • Sarah Pradel
  • Julien Magne
  • Arnaud Jaccard
  • Bahaa M. Fadel
  • Cyrille Boulogne
  • Vera Maria Cury Salemi
  • Thibaud Damy
  • Victor Aboyans
  • Dania MohtyEmail author
Original Paper

Abstract

Cardiac involvement in systemic light chain (AL) amyloidosis carries a poor prognosis mainly through involvement of the left ventricular (LV) myocardium. Despite its limitations, two-dimensional transthoracic echocardiography (2D-TTE) remains the main tool used for the assessment of LV systolic function in AL patients. We hypothesize that 3D-TTE coupled with speckle tracking imaging allows earlier detection of LV systolic dysfunction than 2D-TTE in AL amyloidosis. We prospectively studied 71 subjects including 58 patients with confirmed AL amyloidosis (mean age 66 ± 10 years, 60% male) and 21 healthy control (mean age 64 ± 7 years, 48% male) from 2011 to 2014 at the University Hospital of Limoges. The AL patients were divided into three groups according to Mayo Clinic (MC) staging and all subjects underwent 2D-TTE and 3D-TTE at the same setting. Using 2D-TTE, there was no significant difference in LV ejection fraction (EF) between the groups [LVEF = 63 ± 7% (control), 59 ± 6% (MC stage I), 60 ± 8% (MC stage II) and 57 ± 14% (MC stage III) (p = 0.24)]. In contrast, 3D-TTE demonstrated significantly worse LV systolic function in stage II and III patients using 3D-LVEF [MC II and III 45 ± 8% and 39 ± 12% vs. control 53 ± 8% (p < 0.0001)], global longitudinal strain (GLS) [MC II and III − 11 ± 4% and − 8 ± 3% vs. control − 15 ± 3% (p < 0.0001)] and global radial strain (GRS) [MC II and III 14 ± 9% and 10 ± 8% vs. control 25 ± 10% (p < 0.0001)]. Furthermore, MC III patients had significantly worse global circumferential strain and area tracking [− 17 ± 6% and − 25 ± 8% vs. − 24 ± 7% and − 36 ± 7% for control (p < 0.0001)]. Additionally, MC I had significantly better 3D GLS, GRS and global strain (− 15 ± 3%, 25 ± 10% and 28 ± 12%) than MC II (− 11 ± 4%, 14 ± 9% and 16 ± 10%) and MC III patients (− 8 ± 3%, 10 ± 8% and 12 ± 8%), respectively. Despite an apparently preserved LVEF by 2D-TTE, AL patients in MC stage II and III demonstrate evidence of LV systolic dysfunction by 3D imaging using LVEF and strain analysis. Worse LV involvement by AL amyloidosis was associated with more impaired 3D-TTE LV systolic parameters.

Keywords

Light chain amyloidosis 3-Dimensional echocardiography Left ventricular function 

Notes

Acknowledgements

Mrs. Frederique Wittmer, M.Sc., for her help in some data analysis. Dr. David Lavergne, Ph.D., from the National amyloidosis referral center, for his help in data collection. Mr. David Gibson, Ph.D., for his help in the correction of the manuscript.

Funding

Toshiba provided a complementary machine “Artida Medical System” allowing performance of 2D and 3D TTE in our patient population.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All ethical standards were respected during this work.

Research involving human and animal rights

No animals were involved in our study.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047–2060CrossRefGoogle Scholar
  2. 2.
    Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881–1887CrossRefPubMedGoogle Scholar
  3. 3.
    Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541–4549CrossRefPubMedGoogle Scholar
  4. 4.
    Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A et al (2012) Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 60:1067–1076CrossRefGoogle Scholar
  5. 5.
    Reant P, Barbot L, Touche C, Dijos M, Arsac F, Pillois X et al (2012) Evaluation of global left ventricular systolic function using three-dimensional echocardiography speckle-tracking strain parameters. J Am Soc Echocardiogr 25:68–79.  https://doi.org/10.1016/j.echo.2011.10.009 CrossRefPubMedGoogle Scholar
  6. 6.
    Reant P, Barbot L, Montaudon M, Landelle M, Arsac F, Dijos M et al (2011) Robustness of a new three-dimensional echocardiographic algorithm for left ventricular volume and ejection fraction quantification: experts vs. novices. Eur J Echocardiogr 12:895–903.  https://doi.org/10.1093/ejechocard/jer179 CrossRefPubMedGoogle Scholar
  7. 7.
    Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233–270CrossRefPubMedGoogle Scholar
  8. 8.
    Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420–3427.  https://doi.org/10.1182/blood-2012-12-473066 CrossRefGoogle Scholar
  9. 9.
    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989–995CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328.  https://doi.org/10.1002/ajh.20381 CrossRefGoogle Scholar
  11. 11.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRefGoogle Scholar
  12. 12.
    Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 28:1–39.e14.  https://doi.org/10.1016/j.echo.2014.10.003 CrossRefGoogle Scholar
  13. 13.
    Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107:2446–2452CrossRefGoogle Scholar
  14. 14.
    Bellavia D, Pellikka PA, Abraham TP, Al-Zahrani GB, Dispenzieri A, Oh JK et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. AmJ Cardiol 101:1039–1045CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Sarah Pradel
    • 1
  • Julien Magne
    • 1
  • Arnaud Jaccard
    • 2
  • Bahaa M. Fadel
    • 3
  • Cyrille Boulogne
    • 1
  • Vera Maria Cury Salemi
    • 4
  • Thibaud Damy
    • 5
  • Victor Aboyans
    • 1
  • Dania Mohty
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of CardiologyDupuytren University HospitalLimogesFrance
  2. 2.Department of Hematology, National Reference Center of Light-Chain Systemic AmyloidosisDupuytren University HospitalLimogesFrance
  3. 3.Heart CenterKing Faisal Specialist Hospital & Research CenterRiyadhSaudi Arabia
  4. 4.Hospital das Clínicas da Faculdade de Medicina da Universidade de São PauloSão PauloBrazil
  5. 5.Department of CardiologyAP-HP, Henri Mondor University HospitalCreteilFrance

Personalised recommendations